Status:
UNKNOWN
Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype
Lead Sponsor:
The Nazareth Hospital, Israel
Conditions:
Anemia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Anemia is a common disorder in CKD patients. It is largely attributed to decreased erythropoietin (EPO) production and iron deficiency. Therefore, besides EPO, therapy includes iron replenishment. How...
Detailed Description
This study will include at least 25 anemic CKD patients (stages 3-4) that will be given a weekly IVIR (Sodium ferric gluconate, \[125 mg/100 ml\] for 8 weeks, and during weeks 5-8 also received Carnit...
Eligibility Criteria
Inclusion
- Patients that have been diagnosed as suffering from chronic kidney diseases at stages 3-4 and confirmed by MDRD.
- CKD patients with Hb of less than 10 g%.
- At age ≥18 y.
Exclusion
- Pregnant women.
- Patient with CKD stage 5 on Dialysis.
- Patients with severe liver diseases.
- Patients with severe CHF.
- Inter-current illness such as fever.
- Allergic rhinitis.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02312414
Start Date
October 1 2014
Last Update
May 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nazareth hospital (EMMS)
Nazareth, Israel